Synonyms: Zemplar®
paricalcitol is an approved drug (FDA (1998))
Compound class:
Metabolite or derivative
Comment: Vitamin D receptor agonist
|
|
No information available. |
Summary of Clinical Use |
Used in the treatment of secondary hyperparathyroidism associated with chronic kidney disease. |
Mechanism Of Action and Pharmacodynamic Effects |
Binding of the vitamin D receptor by paricalcitol results in activation of vitamin D responsive pathways. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com |